In a study of 7,422 nursing home residents with type 2 diabetes, 17% met the criteria for glycemic overtreatment and 23% met the criteria for potential overtreatment. (Journal of the American Geriatrics Society)
Aeterna Zentaris has announced some delays in enrolling patients for its pivotal Phase III efficacy and safety study DETECT of 1 mg/kg macimorelin acetate (AEZS-130-P02) as a growth hormone stimulation test in pediatric patients suspected of growth hormone deficiency.
A Welsh couple have been charged with death of their 16-year-old daughter after they allegedly let her progress to morbid obesity and failed to obtain medical treatment for her. (The Guardian)
An Australian study of 193 young adults who were designed using assisted reproductive technology found that they had a better quality of life, particularly in the areas of social relationships and the environment, compared to those who were naturally conceived. (Human fertility)
fermented okra: the next frontier in the fight against obesity? (ScienceDaily)
Allergan and Apollo Endosurgery beat a False Claims Act lawsuit in a Maryland court after a whistleblower alleged the companies redeem purchases from their Lap Band device for the free advertising of surgeons. (Bloomberg Law)
One year of treatment with verapamil, a medicine for high blood pressure (Verelan) was associated with better beta-cell insulin production in people with type 1 diabetes, reducing the amount of insulin needed. (Nature Communication)
The FDA has cleared Amolyt Pharma’s Investigational New Drug Application for the ongoing proof-of-concept clinical trial of AZP-3601an investigational peptide therapeutic, in patients with hypoparathyroidism, with first-line data expected in mid-2022.
Rani Therapeutics has announced the initiation of a Phase I study of RT-102 — an oral version of analog of human parathyroid hormone PTH(1-34) — for the treatment of osteoporosis.